2 stocks are not downer for sure: NantKwest Inc. (NK) and Puma Biotechnology Inc. (PBYI)

On Dec 16, Thomas John C, Director sold 10,000 shares of NantKwest Inc. (NASDAQ: NK), with the average selling price of the stock being $3.14 per share. The total amount realized from this sold $31,400. A document was filed with the Securities and Exchange Commission to notify the public about the sold of the shares.

In addition to that, Director – Thomas John C sold an extra 20,000 shares of this stock in a transaction that took place a day before, on Dec 13, with a share sold at an average of $2.73 and a total of $54,600 was realized from this transaction. After the transaction, the Director – Thomas John C was left with 340,069 shares of the company’s stock, which is currently worth around $928388.37.

The recent price movement of NK means that it is now up by 39.06% from its 52-week high and 615.79% up against its 52-week low prices. Over the past one week, the price volatility of NK stands at 28.69% while the volatility over the past one month is 22.54%. The beta score for this stock is 2.87. A beta score below 1 means that the stock has a low volatility while above 1 signifies that a stock is highly volatile at that particular moment, a data that traders use to keep tabs on their investments.

The company on 11/27/2019 published its latest quarterly earnings, with the report showing that the company recorded -0.22 earnings per share (EPS) during that period. This report was above the expectations of analysts of -0.31 by 0.09.

The shares of NantKwest Inc. (NK) gained by 91.01%, leading to a gain of $3.24 per share, and saw NK end the trading session at $6.80 on Monday 01/13/20. NK started the trading session at $3.56, before reaching a daily high of $6.80. It wasn’t able to sustain that growth though and soon jumped to hit a daily low of $3.46.

The trading volume on Monday stood at 3806447, which was below the stock’s 3-month average volume of 659.13K shares, out of a total 27.73M shares. As the price of the stock climbed, the market valuation of the company gained to 653.82 million.

The shares of Puma Biotechnology Inc. (NASDAQ: PBYI) went down by -8.43% by the end of the recent trading session. This movement saw its price plunge to close at $7.71, which was lower than the previous closing price of $8.42. Over the past one week, the price of PBYI has slipped by -4.34%, while it has recorded a loss of -11.28% over the past one month. Its three-month performance saw PBYI gain 8.13% while its six-month performance saw it drop by -31.28%. The situation is different though over the past one year, as the stock price went down by -67.04%, while its year-to-date (YTD) price performance slipped by -11.89%. The stock price has gone up by +23.16% compared to its 90-day low, while it is down -30.54% compared to its 90-day high price.

Let’s take a look at its short, medium and long-term indicators. Composite Indicators shows that Trendspotter rated the stock as a Sell. In the short-term, the stock has a 20-day average volume of 1,605,215 shares, with the short-term indicators averagely rating the stock as a 50% Sell. A look at its medium-term indicators reveals that it has a 50-Day average volume of 1,781,490 shares and the indicators have an average rating of 100% Sell. The last indicators, the long-term see PBYI stock with a 100-Day average volume of 1,635,469 shares, giving it an average rating of 100% Sell. A look at the general picture of all short, medium and long-term indicators leaves PBYI with an average rating of 88% Sell.

Several brokerage firms sent out their reports PBYI stock not long ago. In its report sent out on October 08, 2019, Goldman lowered its ratings on PBYI from a Neutral to a Sell. In an earlier report on May 10, 2019, Citigroup Downgrade the stock from a Buy to a Neutral. Cantor Fitzgerald meanwhile in its report on May 10, 2019 Downgrade its rating of the stock from a “Neutral” to “Neutral”.

In a recent SEC filing, the company revealed that 175 institutions currently hold the PBYI stock. In the last quarter, a 36,478,343 PBYI shares were in the possession of institutions. On the other hand, the company recorded 36 new institutions who bought it their stock, while 30 institutions sold their entire PBYI reserve. Of the current institutions investing in the stock, 90 increased their investment while 59 decreased their investment in the stock.